Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
The Oncology Institute, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
68236X100 (CUSIP Number) |
Ravi Sarin 10207 Clematis Ct, Los Angeles, CA, 90077 (424) 333-0154 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/26/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 68236X100 |
| 1 |
Name of reporting person
Ravi Sarin | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
4,109,771.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.7 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Rows 8, 10 and 11 represents shares of Issuer's Common Stock received by OncologyCare Partners, LLC ("OncologyCare Partners") in connection with the business combination of the Issuer, which is the subject of the Issuer's Form 8-K filed with the Securities and Exchange Commission ("SEC") on November 18, 2021, as amended on November 19, 2021 ("November 2021 Form 8-K"). Row 13 is calculated based on an aggregate of 87,759,739 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 75,753,229 shares of common stock of the Issuer outstanding as of March 10, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 26, 2025; and (ii) 12,006,510 shares of Common Stock issued by the Issuer on March 26, 2025 in a private placement (the "Private Placement") disclosed on the Issuer's Current Report on Form 8-K filed with the SEC on March 27, 2025.
SCHEDULE 13D
|
| CUSIP No. | 68236X100 |
| 1 |
Name of reporting person
OncologyCare Partners, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
4,109,771.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.7 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Rows 8, 10 and 11 represents shares of Issuer's Common Stock received by OncologyCare Partners in connection with the business combination of the Issuer, which is the subject of the November 2021 Form 8-K. Row 13 is calculated based on an aggregate of 87,759,739 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 75,753,229 shares of common stock of the Issuer outstanding as of March 10, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 26, 2025; and (ii) 12,006,510 shares of Common Stock issued by the Issuer on March 26, 2025 in the Private Placement disclosed on the Issuer's Current Report on Form 8-K filed with the SEC on March 27, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
The Oncology Institute, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
18000 Studebaker Road, Suite 800, Cerritos,
CALIFORNIA
, 90703. | |
Item 1 Comment:
Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends certain Items of the Schedule 13D originally filed with the SEC on November 22, 2021 (the "Original Schedule 13D" and together with Amendment No. 1, the "Schedule 13D"). Except as set forth below, all previous Items are unchanged. This Amendment No. 1 is being filed to disclose that the Reporting Persons are no longer the beneficial owners of more than 5% of the Issuer's Common Stock due to dilution caused by the Issuer's issuance of shares in the Private Placement. | ||
| Item 2. | Identity and Background | |
| (a) | The Schedule 13D is filed by Ravi Sarin and OncologyCare Partners, LLC, a Delaware limited liability company ("OncologyCare Partners" and collectively with Mr. Sarin, the "Reporting Persons"). OncologyCare Partners is managed by OncologyCare Holdings, LLC ("OncologyCare Holdings"), a Delaware limited liability company. Mr. Sarin is the sole managing member of OncologyCare Holdings, and continues to have the ability to influence the vote and disposition of the shares in certain circumstances, and thus may be deemed to indirectly beneficially own the shares held by OncologyCare Partners. Mr. Sarin disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | |
| (b) | The business address of each of Ravi Sarin, OncologyCare Partners and OncologyCare Holdings is 10207 Clematis Ct., Los Angeles, CA 90077. | |
| (c) | Mr. Sarin is Co-Head and Founding Partner of AEA Growth, an investment firm, and Founder and Managing Partner of ROCA Partners, a growth equity investment firm. OncologyCare Partners is the investment vehicle used by ROCA Partners in connection with its investment in the Issuer. | |
| (d) | During the last five years, neither of the Reporting Persons nor OncologyCare Holdings has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). | |
| (e) | During the last five years, neither of the Reporting Persons, nor OncologyCare Holdings, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activity subject to, federal or state securities laws or finding any violations with respect to such laws. | |
| (f) | See Row 4 of each Reporting Person's cover page to this Amendment No. 1. OncologyCare Holdings is a Delaware limited liability company. | |
| Item 4. | Purpose of Transaction | |
Item 4 is hereby supplemented as follows: On August 31, 2023, Mr. Sarin resigned, effective immediately, as a director of the Board of Directors of the Issuer, including any positions held as a member of any committee of the Board. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | See Rows 11 and 13 of each Reporting Person's cover page to this Amendment No. 1. | |
| (b) | See Rows 7 through 10, inclusive, of each Reporting Person's cover page to this Amendment No. 1. | |
| (c) | Neither of the Reporting Persons nor OncologyCare Holdings has effected any transactions in the Issuer's Common Stock within the past 60 days. | |
| (d) | Not applicable. | |
| (e) | As of March 26, 2025, as of a result of the shares issued in connection with the Private Placement, the Reporting Persons have ceased to be the beneficial owners of more than five percent (5%) of the shares of the Issuer's Common Stock outstanding. The filing of this Amendment No. 1 constitutes an exit filing for each of the Reporting Persons. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|